Skip to main content
. 2009 Oct 18;24(Suppl 2):383–388. doi: 10.1007/s11606-009-1037-2

Table 1.

Aromatase Inhibitor Trials of Early Breast Cancer Treatment

Trial AI Duration (months) N Disease-free survival (Hazard Ratio, 95% CI)
Concurrent trials (tamoxifen vs. AI)
ATAC6 Anastrozole 30.7 9366 Stopped due to lack of benefit
Head to head trials (tamoxifen vs AI)
ATAC6 Anastrozole 47 6241 0.86 (0.76–0.99)
BIG 1–9813 Letrozole 41 8028 0.82 (0.71–0.95)
Switch trials (tamoxifen for 5 years vs. tamoxifen for 2–3 years followed by AI for 2–3 years)
Meta-analysis12 Anastrozole 30 4006 0.59(0.48–0.74)
IES7 Exemestane 30.6 4724 0.67(0.56–0.82)
Extended adjuvant trials (tamoxifen for 5 years followed by AI for 5 years vs. placebo for 5 years)
NCIC CTG MA.178 Letrozole 5187 0.58(0.45–0.76)
NSABP15 Exemestane 1598 1.20 (0.57–2.52)

aromatase inhibitor, Arimidex, Tamoxifen Alone or in Combination trial, Breast International Group 1-98 trial, Intergroup Exemestane Study, National Cancer Institute of Canada Clinical Trials Group, National Surgical Adjuvant Breast and Bowel Project B-33 trial.